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Background: Despite numerous discoveries regarding the molecular genesis and progression of
primary cancers, the biology of metastasis remains poorly understood. Compared to very large
numbers of circulating tumor cells that are now known to accompany nearly all cancers, a relatively
limited number of lesions actually develop in most patients with metastases. We hypothesized that
phenotypic changes driven by differential gene expression in a finite subpopulation of tumor cells
render those cells capable of metastasis and sought to identify key pathways through analysis of
gene expression in primary and metastatic lesions from the same patients.
Methods: We compared whole-genome expression in 4 matched samples of primary and
metastatic sarcoma, then evaluated candidate genes with differential expression via quantitative
PCR in 30 additional matched sets, tumor tissue immunostaining, siRNA loss-of-function in a
sarcoma cell migration assay, and clinical correlation with overall and disease-free survival
after metastasectomy.
Results: Comparison of microarray signals identified differential expression of cell adhesion
genes, including upregulation of KRT7 and MUC1 in metastases; KRT7 and MUC1 upre-
gulation was confirmed in 22 (73%) and 20 (67%) matched sets of metastatic/primary
tumors, respectively. Silencing of KRT7 and MUC1 via targeted siRNAs suppressed sarcoma
cell migration in vitro, and a significant correlation (two-sided) was observed between both
KRT7 and MUC1 expression in metastases and overall patient survival.
Conclusion: KRT7 and MUC1 may play a significant role in enabling sarcoma metastasis,
and they may therefore be important prognostic biomarkers as well as potential targets for
therapeutic prevention of metastasis.
Keywords: sarcomas, differential expression, metastasis, microarray, MUC1, KRT7
Introduction
Metastasis and invasion of adjacent vital structures are the primary causes of cancer-
related deaths. Metastasis is often associated with advanced growth of primary
tumors, but in some cancers, such as small cell lung cancer, they can also be seen
commonly when primary tumors are still small. Despite the importance of metastasis
in defining the virulence of cancer and determining patient prognosis, little is under-
stood about the biological and molecular mechanisms responsible for the emergence
of metastasis during the natural history of malignancies, nor has it been established
whether metastatic potential is an early or late phenotypic element in most cancers.1–5
Malignant tumors are known to consist of heterogeneous subpopulations of cells
harboring a range of genetic, biochemical, and immunological characteristics, and
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gene expression analysis is a relatively recent addition to
the profiling of tumor specimens.6–8 It has also relatively
recently been observed that nearly all cancers are asso-
ciated with the release of thousands of tumor cells into the
systemic circulation;9–12 yet the number of macroscopic,
detectable metastases in most patients is much smaller.
Given the establishment of these two elements in our
evolving understanding of tumor biology, we therefore
hypothesized that only a small subpopulation of the cells
shed from a primary tumor into the systemic circulation
bear a specific metastatic phenotype that supports the
development of a successful metastasis in distant tissues.
We further hypothesized that analysis of differential pat-
terns of gene expression between primary tumors and
metastatic lesions from the same patients could begin to
yield important indicators of molecular elements that
define and characterize that phenotype. Prior studies have
begun to examine potentially meaningful patterns of dif-
ferential gene expression between primary tumors and
their associated metastatic lesions.13–21 These studies,
however, have remained largely descriptive and few have
attempted to relate patterns of expression to clinical corre-
lates or demonstrations of functional significance.
Sarcomas are rare malignant tumors of mesenchymal
origin. Localized sarcomas can often be treated effectively
with surgery and radiation. However, sarcoma metastasis,
which develops most commonly in the lungs and occurs in
roughly 35–40% of sarcomas, generally responds poorly to
systemic therapies. Metastatic sarcoma is therefore asso-
ciated with relatively poor prognosis.22,23 As with other
malignancies, a better understanding of the underlying
molecular mechanisms that contribute to metastases is
required in order to develop more effective treatment
strategies for sarcoma. The propensity of sarcomas to
metastasize chiefly to the lungs has justified a more
aggressive surgical approach to pulmonary metastasis. In
this study, we analyzed matched pairs of primary and
metastatic sarcomas to identify candidate genes that play
an important role in this critically important yet poorly
understood element of cancer biology.
Materials and methods
Patient samples
Snap-frozen, banked tumor samples and formalin-fixed,
paraffin-embedded (FFPE) samples were obtained from
patients (age >18 years at the time of operation) who
underwent resection of pulmonary metastatic sarcoma at
the University of California San Francisco (UCSF)
between 1997 and 2012. Demographics and pathologic
characteristics were obtained through chart review. Vital
status and date of death were determined by chart review,
institutional cancer registry, California Death Records, and
the Social Security Death Master File. The institutional
review board at UCSF approved the study, UCSF IRB
approval #10–01111, which was conducted in full accor-
dance with the Declaration of Helsinki. Although the study
was exempt from patient consent for de-identified, retro-
spective analysis of clinical data and FFPE tissue, patients
provided written informed consent prior to intra-operative
tissue specimen collection.
Microarray analyses
The mRNA expression level of samples was measured by
Affymetrix GeneTitan Gene ST 1.1 array. Total RNA of
tissues was extracted from tumor samples that had been
snap frozen in the operating room in liquid nitrogen using
Qiagen RNeasy Mini Kit. A total of 250 ng of total RNA
was amplified into cRNA and made into cDNA using the
Ambion WT Expression Kit. A total of 5.5 µg of the
cDNA was then fragmented using the Affymetrix
GeneChip WT Terminal Labeling kit and confirmed by
running on the Agilent Bioanalyzer using the RNA 6000
kit. The labeled fragmented cDNA was added into the
hybridization cocktail that was prepared according to the
protocol included in the Affymetrix GeneTitan
Hybridization Wash and Stain kit. The samples were then
put onto hybridization trays and loaded into the
Affymetrix GeneTitan MC at the UCSF Thoracic
Oncology Laboratory for hybridization, washing, and
scanning. The Log2-scale expression data were extracted
using the built-in Robust Multi-array Average (RMA)
algorithm in the Affymetrix software. mRNA expression
profiles were compared between matched primary and
metastatic sarcoma tissue to obtain gene expression
changes.
Cell lines and reagents
Sarcoma cell lines U2OS (osteosarcoma), MES-SA (uter-
ine sarcoma), and SKUT1 (leiomyosarcoma) were
obtained from ATCC (Manassas, VA), as was rhabdoid
tumor cell line A204 (rhabdoid tumors bear a
SMARCB1 mutation and are mostly found in small chil-
dren). Cells were cultured with 10% fetal bovine serum
and 2% antibiotics (Penicillin-Streptomycin) by following
the manufacturer’s recommendations for growth media.
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Quantitative real-time PCR
Total RNA was extracted from FFPE tissue according to
the manufacturer’s protocol by using a kit Ambion® (Life
Technologies). Briefly, eight serial 10-μm FFPE sections
were de-paraffinized, after which Proteinase K was added.
After a few washes, total RNA was eluted and genomic
DNA was digested by DNAse I. Subsequent RNA clean-
up was performed by using an E.Z.N.A.® MicroElute
RNA Clean Up Kit (Omega Bio-tek). RNA extracted
from FFPE tissue samples was used only if a 260:280
ratio of 1.6 or greater was observed. The cDNA was
transcribed by using an iScript cDNA Synthesis Kit
(Bio-Rad) which served as a template for real-time PCR
(Applied Biosystems 7000 sequence detection system).
Real-time quantitative reverse transcript-polymerase
chain reaction (qRT-PCR) for Keratin, type II cytoskeletal
7 (KRT7), and Mucin-1 (MUC1) was performed with
SYBR Green, using gene-specific PCR primers (Table 1).
GAPDH was used as a housekeeping gene and data were
analyzed using Relative Quantification Software (Applied
Biosystems). The qRT-PCR data were presented as fold
change in target gene expression±standard deviation. Real-
time PCR reactions were performed in triplicate and the
data were used to calculate fold change in target gene
expression (mean±SD) after normalization with GAPDH,
followed by presentation of the ratio of metastatic/primary
levels.
Immunohistochemistry
Immunohistochemistry (IHC) staining was performed using
a mouse anti-KRT7/17 monoclonal antibody (Invitrogen)
and a mouse anti-MUC-1 monoclonal antibody (R&D
Systems) at dilutions of 1:100–200. Five μm tissue sections
from primary tumor, metastatic tumor, and adjacent normal
lung tissue were de-paraffinized using xylene. Heat-
mediated antigen retrieval was performed using sodium
citrate buffer (10 mM sodium citrate, 0.05% Tween 20,
pH 6.0). Antibody staining was visualized with DAB
(Histostain Plus Broad Spectrum, Invitrogen) and hematox-
ylin counterstain (Fisher Scientific). Representative images
at 400× were examined for positive staining in each primary
sarcoma and matched metastatic sarcoma.
RNA interference (RNAi)
Cells were grown in 6-well plates and transiently transfected
with KRT7 or MUC1-specific small interfering RNA
(siRNA). The siRNA oligos were obtained from
Sigma (KRT7 siRNA: SASI_Hs02_00339809 &
SASI_Hs01_00243071; MUC1 siRNA: TRCN0000122938;
siRNA Universal Negative Control #1). Lipofectamine
RNAiMAX Transfection Reagent (Invitrogen) was used for
siRNA transfection according to themanufacturer’s protocol.
Twenty-four hours after siRNA transfection, confluent cells
were subjected to wound-healing assay.
Wound-healing assay
Wound healing was assessed as previously described.24
Briefly, cells were seeded into culture dishes to obtain a
confluent monolayer. After incubating overnight at 37°C,
the cell monolayer was washed with PBS and replaced
with reduced serum medium (2%). Cells were allowed to
acclimatize to low serum conditions for 24 hrs. The cell
monolayer was scratched in lines of equal width with a
200 μL pipette tip and debris was removed by washing
with 500 μL of PBS followed by addition of reduced
serum medium. This was designated as the 0 hr time-point
and images were acquired using a light microscope. Cells
were then incubated and images were acquired at 24 and
48 hrs. To quantify the migration, four wounds were made
for each condition, and cell migration was calculated by
the average of differences in distance between 48 hr and
0 hr time-points. Three measurements were made per
scratch. All experiments were conducted more than three
times, and representative results are presented.
Western blotting
Total protein from KRT7 or MUC1 siRNA transfected
whole-cell lysates was prepared with M-PER buffer
(ThermoFisher Scientific) and supplemented with protease
and phosphatase inhibitors (Roche). Subsequently, protein
concentrations were determined via a Bradford assay.
Table 1 Summary of genes and sequences of primers used for qRT-PCR
Gene Forward primer Reverse primer
GAPDH CAATGACCCCTTCATTGACCC GACAAGCTTCCCGTTCTCAG
KRT7 CATCGAGATCGCCACCTACC GATATTCACGGCTCCCACTCC
MUC1 TCGTAGCCCCTATGAGAAGG CCACTGCTGGGTTTGTGTAA
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Equal quantities of proteins were combined with 5X pro-
tein loading buffer and separated by SDS-PAGE followed
by PVDF membrane transfer. Membranes were blocked
with 5% milk followed by incubation with appropriate
antibodies. Primary antibodies used in these experiments
were: KRT7 (Thermo Scientific #MA1-19045), MUC1
(Cell Signaling #14161T), and GAPDH (Ambion). Blots
were developed with ECL Reagents (Pierce).
Data analysis
For each gene of interest, expression levels in primary
tumor and in metastatic tumor were normalized to mRNA
from pooled normal lung tissue (Clontech). Gene expres-
sion in primary tumors, metastasis, and the ratio of gene
expression in metastasis versus primary tumor were calcu-
lated. Gene–gene interactions were evaluated using the
product of gene expression of two genes of interest (e.g.,
KRT7*MUC1 represented gene–gene interactions between
KRT7 and MUC1). Overall and recurrence-free survival
following surgical resection were assessed by Kaplan–
Meier analysis using a right-censored dataset – high gene
expression was defined as the upper quartile in each data
set. Survival differences were evaluated using a log-rank
test. Associations between gene expression and disease
recurrence were evaluated using a Wilcoxon rank-sum test
after testing for normalcy using a Shapiro–Wilk test.
For all statistical tests, a pre-specified two-sided α of
0.05 was regarded as statistically significant. All statistical
analyses were conducted using STATA/MP 11 (StataCorp
LP, College Station, TX, USA).
Results
Analysis of differential gene expression in
sarcoma patient samples
To identify differential gene expression in paired primary
and metastatic sarcomas, mRNA samples from 4 sets of
patients who underwent surgical resection of both primary
and pulmonary metastatic lesions were subjected to gen-
ome-wide oligonucleotide microarray analysis using the
Affymetrix GeneTitan Gene ST platform (Table S1). For
this genome-wide exploration, we chose to limit our
microarray analysis to RNA from patients whose primary
tumor tissue and pulmonary metastasis samples were snap
frozen in liquid nitrogen in the operating room to ensure
the best preservation of RNA subjected to this extensive
analysis. Although our sample size of four patients did not
support a rigorous statistical analysis of the subsequent
microarray data, the data derived from this higher quality
RNA served as a screening exploration for genes with
potentially large discrepancies in their expression between
primary tumor and metastasis (Table S2).
Patient characteristics, sarcoma sub-type, and other
clinical findings from these four patients with matched
primary and metastatic tumor samples are summarized in
Table 2. We did observe a pattern of differentially regu-
lated gene sets. From our array of 48,226 genes, there
were 593 whose expression differed between primary
tumor and metastasis ≥2 fold (444 up- and 149 down-
regulated in metastatic samples). In particular, we obser-
vationally noted several subgroups of related genes falling
into various functional groupings, including cell adhesion,
chemotaxis, immune function, chromatin assembly, and
blood development (Figure 1A). We focused on gene sets
known to be regulated in response to adhesion modules
specifically because aberration in cell–cell adhesion may
be a critical factor contributing to tumor transformation,
invasion, and metastasis. Among the top gene signatures
identified by this analysis, we found 10 differentially
regulated genes (Figure 1B). We decided to focus on
KRT7 and MUC1 because they are commonly co-
expressed based on functional protein association net-
works available on the STRING database; this functional
co-expression, along with their identification among the
differentially expressed genes in our exploratory microar-
ray analysis, might reflect a functional metastatic pheno-
type that involved expression of both of these genes.25
Confirmation of KRT7 and MUC1
upregulation in sarcoma metastases
compared to primary tumors
To confirm our microarray data, qRT-PCR analyses were
performed on FFPE tissue from both metastatic and
Table 2 Patient characteristics in included gene expression
microarray studies
Sex Age Ethnicity Vital
status
Pathology
M 44 Caucasian Dead Osteosarcoma
F 37 Hawaiian or Pacific
Islander
Dead Ewing’s sarcoma
M 64 Caucasian Dead Metastatic
chondrosarcoma
M 73 Caucasian Alive Metastatic
chondrosarcoma
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primary sarcoma tumors from 30 patients across 13 sar-
coma sub-types. Twenty-four (80%) were identified histo-
logically as high-grade (grade 3 of 3), and 25 were soft
tissue sarcomas (Table 3). KRT7 expression was increased
significantly in 22 metastatic sarcomas compared with
matched primary tumors (73%), 5 showed no change and
3 had a slight reduction (Figure 1C top panel). The trend
was similar for MUC1, with elevated expression in 20
tumors (67%), 3 that showed no change, and 7 that had a
slight reduction (Figure 1C bottom panel). Eighteen (60%)
Figure 1 KRT7 and MUC1 transcriptional and translational programs are upregulated in metastatic sarcoma. (A) Genome-wide expression profiling in sarcoma via an
oligonucleotide microarray revealed gene sets that are up- or downregulated ≥2 fold in metastatic relative to matched primary tumors. We noted several subgroups of
related genes falling into various functional groupings such as cell adhesion and others listed. (B) Selection of KRT7 and MUC1 among the top 10 differentially regulated
genes as they are the only two which are commonly co-expressed based on functional protein association networks. (C) Quantitative real-time PCR analysis of KRT7 and
MUC1 levels in matched metastatic and primary sarcoma tumors from 30 patient samples presented as a ratio of metastatic/primary levels. The results shown are
representative of two independent experiments. Formalin-fixed, paraffin-embedded samples from primary and metastatic sarcomas were stained for expression of KRT7 (D)
and MUC1 (E) via immunohistochemistry. The results shown are representative of two independent experiments.
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of samples demonstrated relatively higher expression of
both genes in metastases versus primary tumors.
Immunohistochemical analysis of KRT7 and MUC1 pro-
tein expression in representative paired samples also gave
consistent results indicating that both proteins were also
upregulated at metastatic sites relative to the primary
tumor (Figure 1D and E).
Clinical correlations of KRT7 and MUC1
expression
The potential clinical significance of increased metastatic
KRT7 and MUC1 expression was supported by Kaplan–
Meier analysis of overall survival from the time of metas-
tasectomy in patients whose metastatic lesions were in the
highest quartiles of either KRT7 or MUC1 expression
(Figure 2A and B). Worse overall survival was associated
with this high level of metastatic expression of either
KRT7 (P=0.01) or MUC1 (P=0.05) compared to patients
whose metastatic tumors had lower expression of these
genes. Although there was no statistically significant asso-
ciation between the level of either KRT7 or MUC1 gene
expression and recurrence of metastasis, interaction analy-
sis suggested that an overlap of high expression of these 2
genes was associated with significantly more rapid recur-
rence within 12 months of resection (Figure 3A,
P=0.0001). Interestingly, patients who experienced a
recurrence of their sarcoma metastases also had higher
expression of MUC1 (P=0.02), but not of KRT7
(P=0.28), in their primary tumors compared to patients
who did not experience recurrent metastasis (Figure 3B
and C).
Table 3 Summary of 30 patients characterized across13 sarcoma
sub-types used for quantitative real-time PCR
Number of
patients
Sarcoma sub-type
1 Alveolar soft part sarcoma (ASPS)
3 Chondrosarcoma
1 Ewing sarcoma
3 Leiomyosarcoma
2 Liposarcoma
1 Malignant peripheral nerve sheath tumor (MPNST)
2 Myxofibrosarcoma
1 Angiosarcoma
2 Osteosarcoma
1 Rhabdomyosarcoma
1 Round cell sarcoma
4 Synovial sarcoma
8 Undifferentiated pleomorphic sarcoma (UPS)
Sex 24 Male (80%); 6 Female (20%)
Median/mean
age
53.5/51±16
Ethnicity 22 Caucasian (73%); 4 African American (13%); 2
Asian (7%); 2 Hispanic (7%)
Vital status 26 Deceased (87%); 4 Alive (13%)
Figure 2 Overall survival and expression level. Kaplan–Meier curves for overall survival in patients with high versus low levels of expression of KRT7 (A) or MUC1 (B) in
their metastatic lesions.
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Suppression of KRT7 and MUC1 reduces
sarcoma cell migration
Epithelial–mesenchymal transition (EMT) occurs when
cells lose their cell–cell adhesive properties followed by
acquisition of migratory potential. EMT is required for
wound healing, tumor invasion, metastasis, and cancer
progression. Wound-healing assays can inform about
EMT status and thus are used as a surrogate to assess
metastatic potential in vitro.26 In the event that sarcoma
metastases are supported by the contributions of upregu-
lated KRT7 and MUC1 expression, then silencing KRT7
and MUC1 by siRNAs would be expected to result in
reduced EMT and therefore reduced wound healing. To
test this hypothesis, we transiently transfected sarcoma cell
lines with siRNAs targeting KRT7 and MUC1.
Administration of KRT7 and MUC1 siRNA in U2OS
osteosarcoma cells, but not control siRNA, reduced the
expression of these target genes as determined by Western
blotting (Figure 4A). Importantly, these knockdowns of
either KRT7 or MUC1 in U2OS osteosarcoma cells also
resulted in a reduction in wound healing in an in vitro
assay (Figure 4B). Furthermore, in addition to this finding
which we quantified in U2OS osteosarcoma cells
(Figure 4C), we observed the same trend in two soft tissue
sarcoma cell lines, SKUT1 (leiomyosarcoma) and MES-
SA (uterine sarcoma), and in rhabdoid tumor cell line
A204 (Figure 4D). These results suggest that KRT7 and
MUC1 may also contribute to cell migration during
metastases.
Discussion
The goal of this study was to find potential prognostic
biomarkers of tumor metastasis and corresponding targets
that might be amenable to therapeutic intervention. We
began with sets of matched primary and metastatic tumor
from four patients that had all been snap frozen in the
operating room, and in which the mRNA was most likely
better preserved than RNA that could be extracted from
FFPE tissues obtained after standard pathology processing.
We subjected the RNA extracted from these higher quality
tissue sources to genome-wide array analysis, and we
observed relevant gene networks with a subset of gene
sets belonging to cell adhesion modules and cytoskeletal
components.
It has been suggested that the expression levels of several
genes related to cell adhesion can be used to predict clinical
outcomes in patients with metastases.27 Furthermore, recent
studies revealed that MUC1 and KRT7 have been associated
with tumor transformation, invasion, and metastasis in multi-
ple other types of cancer.28–35 We therefore selected KRT7
and MUC1 from among the genes found to be relatively
upregulated in metastatic tissues as initial target genes in
this study.
Many genes involved in cell adhesion, chemotaxis, and
immunity have previously been reported to be overex-
pressed in cancer cells.27 For example, MUC1 showed
enhanced expression in colorectal, renal, squamous cell
and gastric, pancreatic carcinomas and lung metastases
from melanoma, prostate, breast, and ovarian carcinomas
Figure 3 Recurrence after initial metastasectomy. (A) Disease-free survival after initial metastasectomy in patients with a high versus low interaction term for KRT7 and
MUC1 expression in their resected metastatic sarcoma lesions. (B and C) Boxplots of relative gene expression of either KRT7 or MUC1 in the primary tumors of patients
who either did (Yes) or did not (No) experience recurrence of their pulmonary metastasis after metastasectomy.
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compared with matched normal controls, and was asso-
ciated with cellular transformation, invasion, and meta-
static potential.28–35 MUC1 has both cell adhesive as
well as anti-adhesive properties, and influences the RAS/
MAPK pathway in immune T-cells.36–41
KRT7 forms part of the cellular cytoskeleton and func-
tions as a membrane-cytoskeletal linker which contributes
to regulation of cell adhesion.42 KRT7 shows enhanced
expression in two cancer types, colorectal and esophageal
squamous cell carcinomas, and is also associated with
cellular transformation.42 Cell adhesion molecules are
thought to play important roles not only in preserving
tissue architecture but also in tumor progression, which
includes changes in morphology, invasion, and metastasis.
Cytoskeletal component levels, such as the degree of ker-
atinization, have been reported to be valuable in identify-
ing patients at risk for developing regional metastases.27
Quantitative RT-PCR analysis of 30 patients’ matched
samples across 13 sarcoma sub-types validated our micro-
array finding of KRT7 and MUC1 upregulation in metas-
tases versus primary sarcoma. Immunohistochemical
staining also confirmed elevated protein expression of
KRT7 and MUC1 in samples of metastatic sarcoma com-
pared to matched primary tumor from the same patient.
Finally, we found that suppression of KRT7 and MUC1
reduces cell migration in an in vitro wound healing/EMT
assay, suggesting that changes in these proteins that are
related to cell adhesive properties and cytoskeletal func-
tion may contribute to sarcoma cell mobility, migration,
and metastases.
Interestingly, high KRT7 and MUC1 expression levels
in sarcoma metastases were correlated for the first time
with worse overall survival in sarcoma. Our data may also
suggest that the interaction of high expression of both of
these genes may also be associated with more rapid recur-
rence of metastatic disease. The very high recurrence rate
for metastatic sarcoma suggests that more accurate prog-
nostic analysis based on the expression levels of key
metastatic factors might enhance personalization of treat-
ment regimens after metastasectomy, including the balance
of aggressive chemotherapeutic versus repeated surgical
approaches. Additional studies will focus more attention
Figure 4 Gene knockdown of KRT7 and MUC1 blocks metastasis. (A) Western blot of U2OS sarcoma cell line subjected to gene knockdown using siRNA directed at KRT7
(Left panel) and MUC1 (Right panel). GAPDH was used as a loading control. (B) Cell migration/wound healing assay on U2OS osteosarcoma cells from (A) were analyzed at
0, 24, and 48 hrs (Left panel: control siRNA; Center panel: KRT7 siRNA; Right panel: MUC1 siRNA). Representative images from three independent experiments in
osteosarcoma U2OS cells are presented and quantified in (C). (D) Relative cell migration/wound healing in several cell lines: leiomyosarcoma SKUT1 cells, rhabdoid tumor
A204 cells, and uterine sarcoma MES-SA cells. The length at Day 2 is subtracted from the length at Day 0. The error bars represent standard deviation. Representative
calculations from three independent experiments are presented.
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on expression profiles including KRT7, MUC1, and other
metastasis-specific candidate genes.
Although accumulated evidence has previously shown
that MUC1 and KRT7 are involved in the progression,
invasion, and metastasis of human cancers, our study is
one of the first attempts to characterize the difference in
transcriptional profiles from metastatic sites in different
patients with sarcoma and the first to implicate MUC1
and KRT7 in sarcoma metastasis. Our findings suggest
that these differentially expressed genes may be important
factors in tumor metastasis. Additional studies, with more
tumor samples and additional clinical follow-up, as well as
further corroboratory experiments, will help determine
specific alternations at the molecular level in patients
with metastasis. These studies, in turn, may provide a
pathway for better prognostic tools and the identification
of actionable biomarkers.
Conclusion
In conclusion, analysis of gene expression profiles by
genome-wide microarray can provide useful information
for clarifying the mechanism underlying the development
and metastasis of sarcomas, not only revealing the differ-
entially expressed genes, but also providing information
for identifying novel diagnostic and therapeutic targets.
Early evidence suggests that KRT7 and MUC1 maybe
two such targets.
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